Cardiovascular disease (CVD) is the leading cause of death among patients with type 2 diabetes (T2D). Among the potential cardiovascular complications of T2DM, stroke is a particularly high risk for patients, especially given the aging population. Increasing rates of diabetes, hypertension, and obesity are also placing a larger population of younger patients at risk for stroke. Some antidiabetic therapies, including certain glucagon-like peptide-1 (GLP-1) receptor agonists, can reduce the CVD risks in patients with T2D and contribute to secondary prevention. Expert faculty discussions in this Phone-a-Friend series will address specific challenge related to the management of patients with T2D, the risk of stroke, and the roles of GLP-1 receptor agonists.